Skip to content
Markets News
Stocks1 min read

Kyverna Completes Miv-cel FDA Application for Stiff Person Syndrome

Makkler Newsroom
November 12, 2026 · Based on reporting by GlobeNewswire

The company is seeking priority review as it prepares for a potential 2027 launch and reports a third-quarter net loss of $41.9 million.

Key takeaways

  • Kyverna completed its rolling BLA submission for miv-cel in stiff person syndrome and requested priority review.
  • The company is preparing for a potential U.S. launch in 2027, if miv-cel is approved.
  • Kyverna reported a third-quarter net loss of $41.9 million.
  • The company said its cash and securities, plus available loan funds, are expected to provide runway into 2028.

Kyverna Therapeutics has completed its rolling Biologics License Application submission for miv-cel, a potential treatment for stiff person syndrome, and is seeking priority review from the FDA. The application is based on data from the company’s KYSA-8 trial.

The FDA has not yet approved the treatment. Kyverna said it is preparing for a potential U.S. launch in 2027, including engaging treatment centers and building patient support and reimbursement services.

For the third quarter ended September 30, Kyverna reported a net loss of $41.9 million, or $0.68 per share. Research and development expenses were $27.0 million, while general and administrative expenses were $15.9 million.

The company had $170.6 million in cash, cash equivalents and marketable securities at quarter-end. Together with amounts available under its amended loan facility, Kyverna expects those funds to support operations into 2028.

Kyverna also said enrollment in its Phase 3 trial of miv-cel for generalized myasthenia gravis remains on track to finish in mid-2027.

Topics
KYTXMiv-cel
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.